Some knee symptoms shouldn't wait for a routine visit

Heat, redness, and swelling can need prompt care

Get prompt medical help when the knee is hot, red, very swollen, and you have a fever. After a fall, get checked if you can't put weight on that leg. Prompt care also matters if the knee looks bent out of place or won't straighten. Spreading redness, drainage, or fever after a shot or other treatment also needs quick help. These problems can't wait for a routine visit.

Use urgent care when the warning signs appear.

Steady soreness can be checked without a rush

An ache that built slowly is different from a sudden injury. Make a regular appointment if it keeps returning, limits walking, or wakes you. Until then, avoid the movement that sharply stirs it up. Keep some gentle motion in your day so the joint doesn't grow stiffer. If heat, cold, or medicine helps, write down how long the relief lasts.

Those notes give the doctor useful facts.

Risk and the full price belong in the same talk

Before a shot, tell the doctor or trained health professional about blood thinners, trouble with bleeding or healing, and recent illness; then ask about any risk of infection, swelling, bleeding, or added soreness. Get written care directions for the days after the shot, including whom to call. Request a written total that includes later visits. If the likely relief isn't worth the risk or cost, saying no is reasonable. A treatment planned ahead isn't urgent, so you can take time.

Read the directions before leaving.

Sources

1. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit.

   Awad G, et al. — Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.. Clinical rheumatology, 2026. DOI: 10.1007/s10067-026-08042-w.

2. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

3. FDA's guidance on the 21 CFR 1271.10(a) criteria of MINIMAL MANIPULATION and HOMOLOGOUS USE is the rule that decides whether a cell or tissue product may be offered as a lightly-regulated 'section 361' HCT/P or requires full drug approval as a 'section 351' biologic. Docket FDA-2017-D-6146; the revised July 2020 version extended the agency's period of enforcement discretion through 31 May 2021 - which has now expired, so products outside 361 need an approved application or an active IND.

   US Food and Drug Administration, CBER and CDRH — Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use. FDA, 2020.

4. FDA's 6 December 2019 public safety notification followed multiple serious adverse events in Nebraska patients treated with unapproved products marketed as containing exosomes. FDA states there are currently no FDA-approved exosome products, that exosomes used to treat human disease are regulated as drugs and biologics subject to premarket review, and that clinics claiming otherwise are 'simply untrue' - naming clinics that also market violative stem cell products.

   US Food and Drug Administration — Public Safety Notification on Exosome Products. FDA, 2019.

5. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.

6. The AAOS third-edition clinical practice guideline for non-arthroplasty management of knee osteoarthritis is the orthopedic profession's own GRADE-style appraisal of the same options a regenerative clinic sells; it is the benchmark against which any 'regenerative' claim on this topic should be read, and it rates the strongest support for exercise, weight loss and self-management rather than for injectables.

   Brophy RH, et al. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. The Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.